Cuaderno de enfermería. Revista científica
Vol. 3(especial 2 enfermería), 93-101, 2025
Sporothrix globosa en Sudamérica: PCR en tiempo real, LAMP y detección basada en TLR2
Sporothrix globosa in South America: real-time PCR, LAMP, and TLR2-based detection
Segundo Moisés San-Lucas-Coque
Katherine Natasha Castillo-Asimbaya
Dainelly Jaileth Beltrán-Gonzabay
Washington Paúl Culqui-Molina
100
REFERENCIAS
1. Ochani RK, Ochani RK, Asad A, Yasmin F, Shaikh S, Khalid H, et al. COVID-19 pandemic:
from origins to outcomes. A comprehensive review of viral pathogenesis, clinical
manifestations, diagnostic evaluation, and management. Infez Med. 2021;29(1):20–36.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
3. Ekpanyapong S, Reddy KR. Liver and biliary tract disease in patients with coronavirus
disease 2019 infection. Gastroenterol Clin North Am. 2023;52(1):13–36.
4. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney
diseases: an early systematic review and meta-analysis. Trop Med Infect Dis. 2020;5(2):80.
5. Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the liver: lessons learnt from
the East and the West, a year later. J Viral Hepat. 2022;29(1):4–20.
6. Naeem M, Bano N, Manzoor S, Ahmad A, Munawar N, Razak SIA, et al. Pathogenetic
mechanisms of liver-associated injuries, management, and current challenges in COVID-19
patients. Biomolecules. 2023;13(2):280.
7. Téllez L, Martín Mateos RM. COVID-19 and liver disease: an update. Gastroenterol Hepatol.
2020;43(8):472–80.
8. Iglesias JRC. Nirmatrelvir plus ritonavir (Paxlovid), a potent SARS-CoV-2 3CLpro protease
inhibitor combination. Rev Esp Quimioter. 2022 Jun;35(3):236–40.
9. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19:
interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J
Antimicrob Agents. 2020 May;55(5):105954.
10. Zamarrón E, Carpio C, Villamañán E, Álvarez-Sala R, Borobia AM, Gómez-Carrera L, et al.
Impact of systemic corticosteroids on hospital length of stay among patients with COVID-19.
Farm Hosp. 2023 Mar;47(2):55–63.
11. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of
optimized dosing design of hydroxychloroquine for the treatment of SARS-CoV-2. Clin Infect
Dis. 2020 Aug 1;71(15):732–9.
12. Salom-Macaya F. Nuevos tratamientos para el manejo de la hepatitis B. Rev Esp Enferm
Dig. 2020;112(Supl 1):S25–30.
13. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of
remdesivir for patients with severe COVID-19. N Engl J Med. 2020 Jun 11;382(24):2327–36.
14. Snijders RJALM, Stoelinga AEC, Gevers TJG, Pape S, Biewenga M, Tushuizen ME, et al. An
open-label randomised controlled trial of azathioprine versus mycophenolate mofetil for
induction of remission in treatment-naive autoimmune hepatitis. J Hepatol. 2024
Apr;80(4):576–85.
15. Téllez-Ávila F. El uso de betabloqueadores en cirrosis: un cambio de paradigma. Endoscopia.
2014 Apr;26(2):70–1.
16. Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis: a review of current methods. Biosens
Bioelectron. 2021 Jan 15;172:112752.
17. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune
durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal population-level
study. Lancet. 2021;397(10279):1075–84.
18. Enrique A, Bruce A, Trujillo Pérez Y, Chiong Quesada M, Simoni A, et al. Practical use of the
laboratory in hepatic diseases. Rev Med Clin Condes. 2019;30(3):215–24.
19. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the
United States population. Hepatology. 2012 Feb;55(2):447–54.
20. Guerra-Ruiz AR, Crespo J, López Martínez RM, Iruzubieta P, Casals Mercadal G, Lalana
Garcés M, et al. Bilirrubina: medición y utilidad clínica en la enfermedad hepática. Adv Lab
Med. 2021;2(4):362–72.